Merck licenses SPR2015, an oral KRAS G12D inhibitor, from SciBrunch
- Merck obtained exclusive global rights to develop, manufacture and commercialize SPR2015 from SciBrunch.
- SciBrunch received a $400 million upfront payment and is eligible for milestone payments, with total potential value of $2.13 billion.
- Merck will record a $400 million pre‑tax charge in third‑quarter 2026 GAAP and non‑GAAP results related to the transaction.
- SPR2015 is a preclinical oral KRAS G12D (ON) molecular‑glue inhibitor showing nanomolar antiproliferative activity and monotherapy efficacy in CDX and PDX models.
Deal terms
Merck acquired exclusive global rights to develop, manufacture and commercialize SPR2015 from SciBrunch under a licence agreement. SciBrunch received $400 million upfront and is eligible for additional development, commercialization and other milestone payments, bringing the total potential aggregate value to $2.13 billion. BofA Securities acted as exclusive financial advisor to SciBrunch. The transaction has closed.
Financial impact
Merck will record a pre‑tax charge of $400 million, or approximately $0.13 per share, to be included in GAAP and non‑GAAP results in the third quarter of 2026 related to this transaction.
Asset profile — SPR2015
SPR2015 is an investigational preclinical oral KRAS G12D (ON) molecular‑glue inhibitor that has demonstrated nanomolar antiproliferative activity in various KRAS G12D‑mutant cell lines with good selectivity over KRAS wild‑type cells. It has shown antitumor efficacy as a monotherapy across multiple in vivo cell‑derived and patient‑derived xenograft (CDX/PDX) models, with preclinical data presented at the 2026 AACR Annual Meeting.
Source: Merck